Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Cash (2016 - 2025)

Historic Change in Cash for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $32.8 million.

  • Collegium Pharmaceutical's Change in Cash rose 13006.59% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.0 million, marking a year-over-year increase of 15447.5%. This contributed to the annual value of -$143.4 million for FY2024, which is 32488.12% down from last year.
  • Per Collegium Pharmaceutical's latest filing, its Change in Cash stood at $32.8 million for Q3 2025, which was up 13006.59% from $21.2 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Change in Cash ranged from a high of $95.8 million in Q1 2023 and a low of -$108.9 million during Q3 2024
  • Its 5-year average for Change in Cash is -$298052.6, with a median of $11.4 million in 2022.
  • Over the last 5 years, Collegium Pharmaceutical's Change in Cash had its largest YoY gain of 68051.36% in 2022, and its largest YoY loss of 101916.07% in 2022.
  • Collegium Pharmaceutical's Change in Cash (Quarter) stood at -$6.8 million in 2021, then surged by 680.51% to $39.6 million in 2022, then plummeted by 149.5% to -$19.6 million in 2023, then surged by 261.37% to $31.6 million in 2024, then grew by 3.63% to $32.8 million in 2025.
  • Its Change in Cash was $32.8 million in Q3 2025, compared to $21.2 million in Q2 2025 and $20.5 million in Q1 2025.